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study reviewed 609 patients with recurrent urticaria who 
received laboratory investigations of CRP and protein elec-
trophoresis, and found that none fulfilled criteria for 
SchS5. We speculated that genetic factors and unrecog-
nized cases might contribute to the low incidence in 
Korea. Physicians should suspect SchS in cases of re-
current urticaria with atypical clinical features. 
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Dear Editor:
Psoriasis is a chronic inflammatory skin disease in which 
interleukin (IL)-17-producing T helper (Th) 17 cells play a 
crucial role1. Topical application of the toll-like receptor 7 
agonist imiquimod (IMQ) on the ear and/or back skin of 
mice is a widely used IL-17-dependent model of psor-
iasis-like skin inflammation2. The transcription factor reti-
noid acid-related orphan receptor γt (RORγt) is required 
for IL-17 production by Th17 cells3. IMQ-induced skin in-
flammation is reduced both in RORγt-deficient mice and 
upon pharmacological inhibition of RORγt activity with 
novel small molecule selective RORγt inhibitors, indicat-
ing that RORγt is crucial for IMQ-induced psoriasis-like 
skin inflammation in mice and suggesting a potential role 
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Fig. 1. Differential effects of digoxin on imiquimod (IMQ)-induced psoriasis-like skin inflammation on the ear and back. IMQ-induced 
skin thickening was assessed in the ear (A, B) and in the back skin (C, D). Thicknesses of the ear (A) and the back skin fold (C; 
left panel) were measured daily with a micrometer, from day 1 or 3 (A and C, respectively) until day 6. The back skin was visually 
scored for erythema and scaling each on a scale from 0∼4 and the sum score (0-8) is presented (C; right panel). Values are presented 
as mean±standard deviation. Mean numbers of epidermal cell layers in the ear (B) and back skin (D) were assessed in H&E stained 
sections. Representative photos are also displayed (scale bar: 50 µm). Statistics were performed using two-way ANOVA with Tukey’s
correction for multiple comparisons. Due to technical difficulties, data from one mouse are missing from the vehicle cream (Veh)-control 
group (B) and from the Veh-digoxin group (D), respectively. 
for RORγt inhibition for treatment of psoriasis4-6.
The cardiac glycoside digoxin, which has been used for 
centuries to treat congestive heart failure and atrial fi-
brillation, binds to RORγt which leads to selective sup-
pression of Th17 cell differentiation and IL-17 production 
in vitro, with therapeutic effects of digoxin demonstrated 
in mouse models of IL-17-dependent disease, e.g., ex-
perimental autoimmune encephalomyelitis and athero-
sclerosis, respectively7,8. To our knowledge, the effects of 
digoxin in models of psoriasis have not been reported and 
the aim of the current study was to investigate whether di-
goxin affects development of IMQ-induced psoriasis-like 
ear and back skin lesions in mice.
A detailed description of study materials and methods can 
be found in Supplementary File 1. In brief, at 8 weeks of 
age, female C57Bl/6J mice received topical Aldara (5% 
IMQ) or vehicle cream daily for 5 days (45 mg on the 
shaved back [1×2 cm area] and 5 mg on the right ear). All 
mice were treated with either intraperitoneal (i.p.) digoxin 
(20 μg/mouse on day 1, 10 μg/mouse on day 3, and 20 
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Table 1. Effects of digoxin on plasma concentrations of IL-17A and SAA and on spleen weight and BW
Total (n) Control Digoxin
IL-17A (pg/ml) 32 Veh 5.36±2.06 6.05±2.28
IMQ  19.05±5.22**       31.60±13.29****,†
SAA (μg/ml) 28 Veh 38.8±44.5 13.6±5.6
IMQ  171.2±111.1*   221.6±98.8***
Spleen weight (mg/g BW) 30 Veh 3.21±0.74 3.14±0.60
IMQ     8.06±1.00****     7.71±0.62****
BW (% of weight on day 1) 31 Veh 100.13±2.00 101.73±1.95
IMQ 102.34±3.31 101.90±4.56
Presented data were collected at study termination in mice receiving topical IMQ or Veh applied to one ear and the back skin.
Values are presented as number only or mean±standard deviation. Statistics were performed with two-way ANOVA using Tukey’s
multiple comparisons. In analyses where total n was not 32 (n=8 in each group), this was due to technical difficulties. The minimal
detection limit for the IL-17A assay was 5 pg/ml, but although the measured IL-17A levels were below 5 pg/ml in 6 out of 16 mice
receiving vehicle cream, these data were included in the two-way ANOVA. IL: interleukin, SAA: serum amyloid A, BW: body weight,
IMQ: imiquimod, Veh: vehicle. *p＜0.05, **p＜0.01, ***p＜0.001, ****p＜0.0001 Veh-control vs. IMQ-control or Veh-digoxin vs.
IMQ-digoxin; †p＜0.01 IMQ-control vs. IMQ-digoxin. 
μg/mouse on days 4 and 5) or saline (control group). The 
digoxin dose was somewhat lower than dosages (20∼40 
μg/d) previously used in other Th17-dependent disease 
models ameliorated by digoxin7,8, but we found that the 
mice were in marked acute distress after the first dose, 
wherefore treatment was avoided on day 2. The mice 
(n=32; 8 mice/study group) were sacrificed on the 6th 
day, 24 hours after the last cream application and i.p. 
treatment. All experiments were performed according to 
the principles stated in the Danish law on animal experi-
ments and were approved by the Animal Experiment’s 
Inspectorate, Ministry of Justice, Denmark (no. 2012-15- 
2934-00119). The investigation conforms with the Guide 
for the Care and Use of Laboratory Animals published by 
the European Parliament (EU directive 2010/63/EU). The 
ethical policy of the University of Copenhagen complies 
with that of the National Institutes of Health (A5846-01).
In mice receiving topical application of vehicle cream, 
there were no discernible skin lesions and digoxin had no 
significant effects on measured variables (Fig. 1, Table 1). 
Digoxin attenuated the IMQ-induced ear thickening at 
days 5 and 6 (day 6: 0.26 vs. 0.30 mm, p=0.001; Fig. 
1A). Histological evaluation showed an inhibitory effect of 
digoxin on IMQ-induced epidermal hyperplasia in the ear 
(2.1 vs. 3.3 epidermal cell layers, p＜0.001; Fig. 1B). 
However, digoxin treatment increased the IMQ-induced 
back skin thickening at day 6 (1.13 vs. 0.94 mm, p＜0.01; 
Fig. 1C), and increased erythema and scaling on the back 
skin (sum score 6.6 vs. 5.4, p＜0.05; Fig. 1C). Also, there 
was no statistically significant effect of digoxin on IMQ-in-
duced epidermal hyperplasia in the back skin (Fig. 1D). 
IMQ application had systemic inflammatory effects with 
induction of splenomegaly, as well as increased plasma 
levels of IL-17A and the acute-phase protein, serum amy-
loid A (SAA) (Table 1). Surprisingly, in mice receiving top-
ical IMQ, digoxin administration led to increased plasma 
concentrations of IL-17A (31.60±13.29 vs. 19.05±5.22 
pg/ml, p＜0.01) whereas plasma levels of SAA, IMQ-in-
duced splenomegaly, and body weight at study termi-
nation were not affected by digoxin (Table 1).
Our data showed that digoxin exerted differential effects 
on IMQ-induced psoriasis-like skin lesions at different ana-
tomical locations, i.e., with reduction of skin lesion for-
mation on the ear and exacerbation of back skin lesions, 
respectively. Interestingly, a similar differential effect on 
ear and back IMQ lesions in mice has been observed after 
topical treatment with sphingosine-1-phosphate (a cell 
growth and immune modulator)9. This may relate to differ-
ences of target tissues (thinner skin, less hair follicles, min-
imal subcutaneous adipose tissue, and diverse lymph 
drainage in ear vs. back skin), the IMQ application proce-
dure (shaving vs. no shaving before application) and IMQ 
dose (5 vs. 45 mg Aldara), respectively. Also, digoxin bio-
availability may differ at the two sites and future studies 
should include local assessment of IL-17A and RORγt ex-
pression, Th17 cell accumulation, and kinetics of radio-
labelled digoxin, respectively, in addition to experiments 
with other RORγt inhibitors4,6. We unexpectedly found 
increased plasma IL-17A levels which is in contrast to re-
duced levels reported in hyperlipidemic apoE-deficient 
mice treated with digoxin for 12 weeks, but the relation-
ship between target tissue and systemic levels of IL-17A in 
experimental models of disease remains poorly defined8. 
Importantly, off-target effects of digoxin may play a role 
since in addition to RORγt inhibition the agent inhibits 
the sodium potassium adenosine triphosphatase (Na+/K+ 
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ATPase) present in all cells and mainly in the heart. Indeed, 
systemic treatment with novel potent selective RORγt in-
hibitors appear to suppress IMQ-induced skin inflam-
mation on both the ears and back of mice, albeit that there 
are no reports on simultaneous effects of these RORγt in-
hibitors on both anatomical locations in the same ani-
mals4,6. In addition, it was recently reported that develop-
ment of psoriasiform lesions after topical IMQ application 
in mice was dependent on unintended oral IMQ ingestion 
and it is possible that some of the systemic effects ob-
served in our study were elicited by systemic IMQ uptake 
rather than skin-driven inflammation10.
The mechanisms responsible for differential effects of di-
goxin on IMQ-induced psoriasis-like skin inflammation on 
the ear and back in mice clearly require more study, but 
our results underline the complexity of the IMQ model 
and support caution in extrapolation of results of targeted 
interventions in this model to human psoriasis.
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